Moreover, dual PD-1 and CTLA-4 blockage combination displayed durable clinical activity and favorable tolerability as the second-line therapeutic regimen for advanced cervical cancer (O'Malley et al., 2022). This evidence concerns the gene PDCD1 and cervical carcinoma.